Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.

Aladdin Healthcare Technologies SE trades as ALDNF on OTC. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Aladdin Healthcare Technologies SE can be compared against peers such as Advanced Proteome Therapeutics Corporation, Eden Empire Inc., MedMen Enterprises Inc., Miravant Medical Technologies Inc., Ontrak, Inc., Pivotal Therapeutics Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $160,415, beta of 0.55, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ALDNF currently shows total debt of N/A and beta of 0.55. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.aladdinid.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.